In vitro and in preclinical models, RT11-i enhanced the antitumor activity of gemcitabine (GEM), the most commonly used chemotherapeutic drug for PDA, suggesting that the use of combined treatment is a potential strategy for patients with KRAS mutations [108]. This evidence concerns the gene KRAS and Patent ductus arteriosus.